Abstract
Objective: Evaluation of transdermal scopolamine for motion sickness prophylaxis.
Method: Randomized, prospective double blind. 2010-11. Twelve patients, 7 male, 5 female, ages 21 to 57. Intervention(s): Off-vertical axis rotation 20° in the dark after administration of transdermal scopolamine or placebo. Outcome measures: Duration of tolerated off-vertical rotation; subjective symptom reporting at 1-minute intervals on a 0 to 4 scale.
Results: Patients treated with transdermal scopolamine had statistically significant improved tolerance time to off-vertical axis rotation. Reported symptomatology on the 0-3 subjective symptom scale was significantly improved as compared to placebo and was dose-dependent. These results were significant to the .05 confidence level.
Conclusion: Off-vertical axis rotation is a useful modality for the evaluation of motion sickness medications. Transdermal scopolamine showed statistically significant dose-dependent effects in mitigating OVAR-induced motion sickness symptomatology and was well tolerated.
Get full access to this article
View all access options for this article.